{"id":578214,"date":"2026-03-31T00:00:00","date_gmt":"2026-03-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-04-21T05:12:02","modified_gmt":"2026-04-21T05:12:02","slug":"algoop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-current-treatment-treatment-algorithms-claims-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-current-treatment-treatment-algorithms-claims-data\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Wet Age-Related Macular Degeneration (US)"},"content":{"rendered":"<p>The U.S. market for wet age-related macular degeneration (wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options such as Avastin (used off-label) and Regeneron\u2019s Eylea remain widely prescribed, this report examines patient switching patterns toward Regeneron\u2019s Eylea <abbr title=\"high-dose\">HD<\/abbr>, Roche\u2019s Vabysmo, and a biosimilar version of Eylea (Amgen\u2019s Pavblu). It also evaluates whether the off-label use of compounded Avastin as a first-line therapy in newly diagnosed patients is changing, signaling shifts in prescribing behavior and competitive dynamics. It examines patient share trends, therapy sequencing, and persistency trends. By analyzing treatment initiation, progression, and patient flow using claims data, this report provides stakeholders with a comprehensive view of evolving patterns that may influence market positioning and strategic planning of their pipeline assets.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key brands garner by line of therapy in newly diagnosed wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients?<\/li>\n<li>How has Amgen\u2019s Pavblu been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key drugs:<\/strong> Avastin, Eylea, Lucentis, Beovu, Vabysmo, Eylea <abbr title=\"high-dose\">HD<\/abbr>,\u00a0Susvimo, Pavblu, biosimilars of Avastin, biosimilars of Lucentis<\/p>\n<div>\n<p><strong>Product description <\/strong><\/p>\n<\/div>\n<div>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW96625708 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<\/div>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-578214","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/578214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/578214\/revisions"}],"predecessor-version":[{"id":578283,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/578214\/revisions\/578283"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=578214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}